MktsMarkets

TScan Therapeutics, Inc.
NASDAQ: TCRXKey statistics
TCRX News
Stories mentioning TCRX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 982.00 | 2,567 | 2,511 | 3,076 | 2,171 | 665.00 | 1,049 | 536.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 21,904 | 20,039 | 31,689 | 32,634 | 29,788 | 29,354 | 26,262 | 26,877 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 30,121 | 26,425 | 39,563 | 41,729 | 38,421 | 37,377 | 33,671 | 34,650 |
| Operating Income (Loss) | (29,139) | (23,858) | (37,052) | (38,653) | (36,250) | (36,712) | (32,622) | (34,114) |
| Interest Income | ||||||||
| Interest Expense | 689.00 | 702.00 | 699.00 | 689.00 | 679.00 | 784.00 | 958.00 | 952.00 |
| Other Expense | 473.00 | 881.00 | 1,342 | 1,701 | 2,123 | 903.00 | 2,735 | 2,453 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (28,666) | (22,977) | (35,710) | (36,952) | (34,127) | (35,809) | (29,887) | (31,661) |
| Earnings Per Share (Basic) | (0.22) | (0.18) | (0.28) | (0.28) | (0.26) | (0.32) | (0.25) | (0.28) |
| Earnings Per Share (Diluted) | (0.22) | (0.18) | (0.28) | (0.28) | (0.26) | (0.32) | (0.25) | (0.28) |
| Weighted Average Shares Outstanding (Basic) | 129,913 | 129,777 | 129,836 | 129,730 | 129,679 | 111,990 | 118,700 | 113,425 |
| Weighted Average Shares Outstanding (Diluted) | 129,913 | 129,777 | 129,836 | 129,730 | 129,679 | 111,990 | 118,700 | 113,425 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TCRX
TScan Therapeutics, Inc. (NASDAQ: TCRX) is a stock listed on the Nasdaq Stock Market under the ticker symbol TCRX. It last traded at $0.2100 (Oct 19, 2026, 4:00 PM ET), down 9.0% on the day. That gives TScan Therapeutics a market capitalisation of $15.7M.
Over the past 52 weeks TCRX has traded between $0.2000 and $2.57.
Revenue for the quarter ended Mar 31, 2026 was $982.0K; a net loss of $28.7M. Revenue was down 54.8% from $2.2M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $982.0K | -$28.7M | -2919.1% |
| Dec 31, 2025 | $2.6M | -$23.0M | -895.1% |
| Sep 30, 2025 | $2.5M | -$35.7M | -1422.1% |
| Jun 30, 2025 | $3.1M | -$37.0M | -1201.3% |
From TScan Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…